Michael Dal Molin
Overview
Explore the profile of Michael Dal Molin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rabodoarivelo M, Hoffmann E, Gaudin C, Aguilar-Ayala D, Galizia J, Sonnenkalb L, et al.
STAR Protoc
. 2025 Mar;
6(1):103643.
PMID: 40067825
Here, we present a protocol to perform a time-kill assay (TKA) to quantify bacterial burden at multiple time points using colony-forming units and most probable number readouts simultaneously. We describe...
2.
Torres-Gomez H, Keiff F, Hortschansky P, Bernal F, Kerndl V, Meyer F, et al.
Eur J Med Chem
. 2024 Sep;
279:116849.
PMID: 39265253
Nitrobenzothiazinones (BTZs) are undergoing late-stage development as a novel class of potent antitubercular drug candidates with two compounds in clinical phases. BTZs inhibit decaprenylphosphoryl-β-d-ribose oxidase 1 (DprE1), a key enzyme...
3.
Design, synthesis and antimycobacterial activity of imidazo[1,5-]quinolines and their zinc-complexes
Marner M, Kulhanek N, Eichberg J, Hardes K, Dal Molin M, Rybniker J, et al.
RSC Med Chem
. 2024 May;
15(5):1746-1750.
PMID: 38784461
Tuberculosis has remained one of the world's deadliest infectious diseases. The complexity and numerous adverse effects of current treatment options as well as the emergence of multi-drug resistant (Mtb) demand...
4.
Gries R, Chhen J, van Gumpel E, Theobald S, Sonnenkalb L, Utpatel C, et al.
Cell Chem Biol
. 2024 Jan;
31(4):699-711.e6.
PMID: 38181799
Drug-resistant Mycobacterium tuberculosis (Mtb) remains a major public health concern requiring complementary approaches to standard anti-tuberculous regimens. Anti-virulence molecules or compounds that enhance the activity of antimicrobial prodrugs are promising...
5.
Phelps G, Cheramie M, Fernando D, Selchow P, Meyer C, Waidyarachchi S, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(2):e2314101120.
PMID: 38165935
(), a nontuberculous mycobacterial (NTM) species, is an emerging pathogen with high intrinsic drug resistance. Current standard-of-care therapy results in poor outcomes, demonstrating the urgent need to develop effective antimycobacterial...
6.
Baumann P, Dal Molin M, Aring H, Krumbach K, Muller M, Vroling B, et al.
BMC Biol
. 2023 Sep;
21(1):183.
PMID: 37667306
Background: In contrast to modern rational metabolic engineering, classical strain development strongly relies on random mutagenesis and screening for the desired production phenotype. Nowadays, with the availability of biosensor-based FACS...
7.
Gries R, Dal Molin M, Chhen J, van Gumpel E, Dreyer V, Niemann S, et al.
Antimicrob Agents Chemother
. 2023 Jun;
67(7):e0025123.
PMID: 37358461
Drug-resistant tuberculosis is a global health care threat calling for novel effective treatment options. Here, we report on two novel cytochrome inhibitors (MJ-22 and B6) targeting the Mycobacterium tuberculosis respiratory...
8.
Van Wijk R, Lucia A, Sudhakar P, Sonnenkalb L, Gaudin C, Hoffmann E, et al.
iScience
. 2023 Apr;
26(4):106411.
PMID: 37091238
Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The European Regimen Accelerator for Tuberculosis (ERA4TB) is a public-private partnership of 30+ institutions with the...
9.
Kollmorgen I, Bachmann N, Dal Molin M, Degenhart C, Zent E, Pareek V, et al.
ChemMedChem
. 2023 Mar;
18(11):e202200631.
PMID: 36883965
Due to worldwide increasing resistances, there is a considerable need for antibacterial compounds with modes of action not yet realized in commercial antibiotics. One such promising structure is the acetyl-CoA...
10.
Dieterich C, Probst S, Ueoka R, Sandu I, Schafle D, Dal Molin M, et al.
Angew Chem Int Ed Engl
. 2021 Dec;
61(8):e202115802.
PMID: 34918870
Genome mining and bioactivity studies suggested the sponge-derived bacterium Aquimarina sp. Aq135 as a producer of new antibiotics. Activity-guided isolation identified antibacterial peptides, named aquimarins, featuring a new scaffold with...